课题基金 / 基金详情

Molecular and pharmacological validation of Cathepsin S as a novel target in cancer treatment

Molecular and pharmacological validation of Cathepsin S as a novel target in cancer treatment
组织蛋白酶 S 作为癌症治疗新靶点的分子和药理学验证
批准号:
G0901615/1
负责人:
Christopher Scott
金额:
$46.6万
依托单位:
依托单位国家:
英国
项目类别:
Research Grant
财政年份:
2010
资助国家:
英国
项目状态:
已结题
起止时间:
2010 至 --

项目摘要

项目成果

Christopher Scott的其他基金

相似基金

相关文献

中文摘要
翻译
恶性癌症的特征是肿瘤能够侵入其正常周围组织,从而允许其发展和扩散,通常到远端部位/器官。这些继发性肿瘤的发展通常是患者死亡的原因。该提案旨在评估治疗阻断破坏性酶组织蛋白酶S在侵袭性肿瘤的发展和扩散中的潜力。这种蛋白酶由肿瘤和肿瘤相关细胞过度产生,抑制这种蛋白酶在未来可能证明与化疗剂联合使用不仅可以杀死癌细胞,而且可以防止这些继发性转移的扩散和播种。
英文摘要
Malignant cancer is hallmarked by the ability of the tumour to invade its normal surrounding tissue thus permitting its development and spread, frequently to distal sites/organs. The development of these secondary tumours is normally the cause of mortality in the patient. This proposal aims to evaluate the potential for the therapeutic blocking of a destructive enzyme, cathepsin S, in the development and spread of aggressive tumours. Over-produced by tumour and tumour associated cells, the inhibition of this protease may in the future prove useful in combination with chemotherapeutic agents to not only kill the cancer cells but to prevent the spread and seeding of these secondary metastases.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Development of a Chemoproteomics Centre of Excellence: A Prosperity Partnership for Drug Discovery in Northern Ireland
  • 批准号:
    BB/Y00325X/1
  • 项目类别:
    Research Grant
  • 资助金额:
    $335.05万
  • 财政年份:
    2023
  • 负责人:
    Christopher Scott
  • 依托单位:
DRivers and Impacts of Ionospheric Variability with EISCAT-3D (DRIIVE)
  • 批准号:
    NE/W003384/1
  • 项目类别:
    Research Grant
  • 资助金额:
    $3.27万
  • 财政年份:
    2022
  • 负责人:
    Christopher Scott
  • 依托单位:
Development of intracellular VNARs as novel tools to dissect intracellular biological processes
  • 批准号:
    BB/R009112/1
  • 项目类别:
    Research Grant
  • 资助金额:
    $44.16万
  • 财政年份:
    2018
  • 负责人:
    Christopher Scott
  • 依托单位:
Tumor priming sequences combined with novel nanoparticle drug carriers for enhanced therapeutic efficacy in pancreatic cancer: a tripartite USA/Northern Ireland/Republic of Ireland consortium
  • 批准号:
    MC_PC_15013
  • 项目类别:
    Intramural
  • 资助金额:
    $19.11万
  • 财政年份:
    2015
  • 负责人:
    Christopher Scott
  • 依托单位:
海外基金